**Summary**
Aptamer Group PLC, a developer of next-generation synthetic binders for the life sciences industry, announced a new £112,000 contract with a top 10 global pharmaceutical company. This success-based, repeat business agreement focuses on developing Optimer® binders for two protein targets to support biomarker research in complex biological matrices like muscle lysates and plasma. The project, which follows a staged process, builds on Aptamer’s recent achievements, including a £360,000 radiopharmaceutical contract and £315,000 in smaller wins in Q1.
This contract increases Aptamer’s FY26 revenue visibility to £1.14 million, with a robust £3.3 million fee-for-service pipeline, including £1.0 million in late-stage discussions. The deal underscores the growing adoption of the Optimer® platform and diversifies the Group’s revenue streams. Aptamer retains ownership of the binders, supporting future licensing and royalty opportunities.
CEO Dr. Arron Tolley highlighted the contract’s significance in demonstrating Optimer®’s versatility and value, emphasizing the Group’s focus on converting its pipeline into sustainable growth. The announcement reinforces Aptamer’s strong commercial momentum, though the company is not providing formal guidance for FY26 due to variability in contract timings and revenue recognition.